Abstract��OBJECTIVE To introduce the procedure of developing reference standards of fluconazole impurities using fluconazole impurity H as an example and reveal a special problem for establishment of national reference standards. METHODS Firstly, the structure of fluconazole impurity H was validated by infrared, mass spectrum and nuclear magnetic resonance method. Secondly, its purity was determined using the related substances test of fluconazole in European Pharmacopoeia 8.0 (EP8.0) and Chinese Pharmacopeia (2010 version, Volume 2, ChP2010). Then the major impurities determined by the above two HPLC systems were analyzed by LC-MS method. Finally, the content of fluconazole impurity H, its water content and inorganic impurities were determined by quantitative nuclear magnetic resonance (qNMR) method, Karl Fischer titrimetry method and residue on ignition method respectively. RESULTS The structure of fluconazole impurity H was identical with that in EP 8.0. The contents of water and inorganic impurities were 0.05% and 0.04%, respectively. It was found that fluconazole impurity H would be partially degraded into fluconazole impurity G in water solution, which resulted in the inaccuracy of the related substances test. The content of impurity H was 99.5% by qNMR method. CONCLUSION Due to the structural characteristics of fluconazole impurity H, the mass balance method, which is the routine method for determination of the content of reference standards, is not suitable for fluconazole impurity H. In the circumstances, qNMR method can be used as a complementary method for the content determination of reference standards.
����, ����, ��ұ, ���t, ����, Ҧ�г�, ������. ����������H���ұ����ʵ�����[J]. �й�ҩѧ��־, 2018, 53(17): 1516-1522.
FENG Yan-chun, WANG Chen, TIAN Ye, CHANG Yi-zhuo, MA Bu-fang, YAO Shang-chen, HU Chang-qin. Establishment of National Reference Standard of Fluconazole Impurity H. Chinese Pharmaceutical Journal, 2018, 53(17): 1516-1522.
WAN K, ZHANG Y Y, ZHOU H C, et al. Recent advances in antifungal fluconazole. J Chin Antibiotics (�й���������־), 2012, 37(1):8-15.
[2]
LI B. The synthesis of fluconazole and the study on the relationship between quantitative structure and activity of organic compound . Changsha:Central South University, 2005.
[3]
ZHENG X X. Adverse reaction and prevention of fluconazole. Anti-infection Pharm(����Ⱦҩѧ), 2007, 4(1):35-39.
[4]
VAIJANATH G D, PRAVIN P K, PRADEEP D G, et al. Preparative isolation and structural elucidation of impurities in fluconazole by LC-MS/MS. J Pharm Biomed, 2006, 42(3):334-340.
[5]
VAIJANATH G D, PRADEEP D G, PRAVIN P K, et al. Isolation and structural identification of an impurity in fluconazole bulk drug substance. J Pharm Biomed, 2007, 45(4):422-429.
[6]
VASANTHA M, SIVALAKSHMI D A, SURYANARAYANA M. Isolation/synthesis & characterization & potential impurities of antifungal drug, fluconazole. Asian J Biochem Pharm Res, 2011, 4(1):201-208.
[7]
YAN X H, LI C Y, CHEN A L, et al. Determination of related substances in fluconazole bulk drug. Chin Pharm J(�й�ҩѧ��־), 2012, 47(16):1333-1336.
[8]
HOUDA B, YOUNESS B, PHILIPE H, et al. Solid-state characterization and impurities determi nation of fluconazol generic products marketed in Morocco. J Pharm Anal, 2012, 2(6):412-421.
[9]
WANG C G, LIU Z Z, WANG Y N, et al. HPLC Determination of related substances and identification of the largest unknown impurity in fluconazole. Chin J Pharm Anal (ҩ�������־), 2016, 36(7):1243-1251.
[10]
COLIN S C, JAMES W S, DAVID V B, et al. Particle beam-mass spectrometric analysis of difluorophenyl triazole compounds using normal phase-HPLC. Talanta, 1997, 44(6):1025-1035.
[11]
MO A G, XIE Q C, WU R F, et al. Isolation and structure elucidation of a related substance in fluconazole. Chin J Pharm (�й�ҽҩ��ҵ��־), 1995, 26(1):18-19.
[12]
FAN G, ZHANG M Y, ZHOU X D, et al. Quality evaluation and species differentiation of Rhizoma coptidies by using proton nuclear magnetic resonance spectroscopy. Anal Chim Acta, 2012, 747(20):76-83.
2018, Vol. 53 
